Brussels, October 3rd, 2007
Eurofins has agreed with Lantmännen Invest AB to acquire all the shares in Lantmännen Analycen AB, conditional upon satisfactory due diligence to be conducted during October 2007. Analycen has its main activities in Sweden but also has significant testing businesses in Denmark, Norway and Finland. Analycen offers an extremely broad portfolio of laboratory tests of food, feed, agricultural media, the environment and pharmaceutical products. It has a unique position as service provider for the food and farming industry and is well established as one of the main providers of environmental testing services for private industry, consultancy companies and public services. Analycen employs more than 400 employees and has annual revenues of around EUR 40m. So far this year up to the end of August, the company has been loss-making. Subject to completion, this acquisition will bring Eurofins to a position of no. 1 in food, feed and environmental testing in Scandinavia with more than 1100 employees in Sweden, Denmark, Norway and Finland.
For further information about Eurofins please visit www.eurofins.com or contact: Investor Relations Phone: +32-2-769 7383 E-mail: email@example.com
Notes for the editor: Eurofins - a global leader in bio-analysis Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. With over 6,000 staff in more than 100 laboratories across 25 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff. The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both, its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods. As one of the most innovative and quality oriented international player in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world. The shares of Eurofins Scientific are listed on Euronext in the Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).
Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
|EUROFINS SCIENTIFIC||Euronext Paris||400.00 (c)||-0.51%||28 242|